CLINICAL_TRIALS trial_result · 2022-05-16

Clinical Trial Update: Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy [Phase 2]

Phase 2 trial of Zilucoplan in immune-mediated necrotizing myopathy was terminated with posted results in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Ra Pharmaceuticals | Conditions: Immune Mediated Necrotizing Myopathy | Phase 2 | Status: TERMINATED | Results posted: 2022-05-16